NVCR

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 14

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,927 shares

Expires 2027-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested as of the date hereof.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 13

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,840

Underlying: Ordinary Shares · 10,000 shares

Expires 2025-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested as of the date hereof.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 12

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,260

F3 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 11

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 10

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 9

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 8

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,291

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 7

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 6

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 5

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

F2 · price: On August 12, 2021, Ms. Cordova sold 8,026 shares in multiple trades at prices ranging from $140.90 to $140.98. The price reported above reflects the weighted average sale price. Ms. Cordova hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 4

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,019

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 3

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

F1 · price: On August 12, 2021, Ms. Cordova sold 5,927 shares in multiple trades at prices ranging from $140.90 to $141.08. The price reported above reflects the weighted average sale price. Ms. Cordova hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000102 · wf-form4_162879970478058.xml · derivative · entry 2

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Indirect

Disclosed balance after: 1,324

Underlying: Ordinary Shares · 320 shares

Expires 2026-01-12

F1 · derivative.exercise_date: Currently exercisable.

F3 · ownership.nature: By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership.

SEC source: 0001645113-21-000102 · wf-form4_162879970478058.xml · derivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,724

Underlying: Ordinary Shares · 320 shares

Expires 2026-01-12

F1 · derivative.exercise_date: Currently exercisable.

F2 · balance_after: Amended total to correct prior mathematical error.

SEC source: 0001645113-21-000101 · wf-form4_162828263563750.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Indirect

Disclosed balance after: 384

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · ownership.nature: Represents shares indirectly beneficially owned by Mr. Madden that are held by his child with whom he shares a residence. Mr. Madden disclaims beneficial ownership of these shares.

SEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · derivative · entry 3

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,345

Underlying: Ordinary Shares · 1,000 shares

Expires 2028-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested as of the date hereof.

SEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · nonDerivative · entry 2

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,859

F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.

SEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · nonDerivative · entry 1

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.

SEC source: 0001645113-21-000100 · wf-form4_162828248977664.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,169

F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.

SEC source: 0001645113-21-000098 · wf-form4_162811199885199.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,158

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001645113-21-000097 · wf-form4_162811132288298.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,232

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001645113-21-000095 · wf-form4_162811071615273.xml · nonDerivative · entry 1

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,144

F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

SEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 3

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,608

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001645113-21-000098 · wf-form4_162811199885199.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,486

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001645113-21-000096 · wf-form4_162811081937813.xml · nonDerivative · entry 1

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 554,398

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001645113-22-000031 · wf-form4_164703562615399.xml · derivative · entry 3

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,717

Underlying: Ordinary Shares · 3,717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.expiration_date: Fully vested as of the date hereof.

SEC source: 0001645113-22-000031 · wf-form4_164703562615399.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · derivative · entry 4

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,253

Underlying: Ordinary Shares · 651 shares

Expires 2029-07-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested as of the date hereof.

SEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 2

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,144

F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

SEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 1

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

SEC source: 0001645113-21-000089 · wf-form4_162578028082781.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,780

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000082 · wf-form4_162577957572435.xml · nonDerivative · entry 1

Longsworth Todd Christopher · CIK 0001693530 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,868

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000088 · wf-form4_162578019833894.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,199

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000087 · wf-form4_162578013600784.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,993

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000086 · wf-form4_162578004369784.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,080

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000085 · wf-form4_162577994550029.xml · nonDerivative · entry 1

Benaim Ely · CIK 0001632237 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,144

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000084 · wf-form4_162577981023454.xml · nonDerivative · entry 1

Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,302

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000083 · wf-form4_162577972656216.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,886

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021.

SEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · derivative · entry 3

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,345

Underlying: Ordinary Shares · 1,000 shares

Expires 2028-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested as of the date hereof.

SEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · nonDerivative · entry 2

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,859

F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.

SEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · nonDerivative · entry 1

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.

SEC source: 0001645113-21-000080 · wf-form4_162344315214063.xml · nonDerivative · entry 1

Shah Pritesh · CIK 0001744884 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,732

F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.

SEC source: 0001645113-21-000079 · wf-form4_162344303527240.xml · derivative · entry 2

McCoy Sherilyn S · CIK 0001422968 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,499

Underlying: Ordinary Shares · 1,499 shares

Expires 2031-06-09

F2 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

SEC source: 0001645113-21-000079 · wf-form4_162344303527240.xml · nonDerivative · entry 1

McCoy Sherilyn S · CIK 0001422968 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,714

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

SEC source: 0001645113-21-000077 · wf-form4_162344290145800.xml · derivative · entry 2

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,499

Underlying: Ordinary Shares · 1,499 shares

Expires 2031-06-09

F2 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

SEC source: 0001645113-21-000077 · wf-form4_162344290145800.xml · nonDerivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,944

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

SEC source: 0001645113-21-000078 · wf-form4_162344295339216.xml · derivative · entry 3

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,499

Underlying: Ordinary Shares · 1,499 shares

Expires 2031-06-09

F3 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

SEC source: 0001645113-21-000078 · wf-form4_162344295339216.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,620

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.